Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.
Chin Med J (Engl). 2022 Jan 4;135(4):393-399. doi: 10.1097/CM9.0000000000001929.
Interleukins (ILs) and associated cytokines serve as the means of communication for immune cells and non-immune cells. The use of ILs in harnessing the immune system to cancer treatment has been a promising approach. ILs not only nurture an environment enabling cancer growth but also simultaneously trigger a productive tumor-directed immune response. These properties of ILs are increasingly being explored as a strategy to improve the outcomes of cancer. Here, we describe recently innovative technological approaches that have been developed to improve the pharmacokinetics, safety, and efficacies of IL-2, 15, 10, and 18 in the treatment of melanoma. Furthermore, the combination of ILs and immune checkpoint inhibition may synergize to reshape the tumor environment, thus yielding better clinical benefits in the future.
白细胞介素 (ILs) 和相关细胞因子是免疫细胞和非免疫细胞之间通讯的媒介。利用 ILs 来利用免疫系统治疗癌症是一种很有前途的方法。ILs 不仅培育了一个有利于癌症生长的环境，而且还同时引发了一种有效的肿瘤定向免疫反应。这些 ILs 的特性正被越来越多地探索作为一种提高癌症治疗效果的策略。在这里，我们描述了最近开发的创新技术方法，以提高 IL-2、15、10 和 18 在治疗黑色素瘤中的药代动力学、安全性和疗效。此外，ILs 与免疫检查点抑制的联合使用可能会协同作用，重塑肿瘤环境，从而在未来带来更好的临床获益。
